Researchers have developed a new laboratory technique, which allows
them to change sequences within a DNA molecule. The tool is set to
have positive implications in DNA lab-based medical diagnosis and
Bentley has accelerated the path to launching its novel intranasal
spray insulin, signing a license agreement with India's Biocon to
develop and market the product in 85 countries throughout Asia,
Africa, and the Middle East.
Merck is to cut 7,000 jobs, close five factories and three research
facilities, as the US pharmaceutical company continues to suffer
from the devastating repercussions caused by its painkiller Vioxx
and the pending lawsuits.
Schott Pharmaceutical Packaging will be the first international
manufacturer of primary pharmaceutical glass packaging to establish
a production site in China, in a move that will increase supply to
Chinese injectable drug manufacturers...
Hopax Fine Chemicals is building a new facility in Kaohsiung,
Taiwan, in a move to raise current production capacity by five
folds and become one of the top providers for biological buffers
and specialty chemicals for the pharmaceutical...
SemBioSys Genetics has demonstrated bio-equivalence of a
plant-produced insulin, which if realised, could become a viable
alternative to meet the demand for insulin as the incidence of
diabetes increases worldwide.
Researchers have developed a new catalyst process that offers
faster reaction rates, a substantially higher product yield and a
cleaner production process than is currently available in the
pharmaceutical and chemical industry.
Alcan has acquired the outstanding minority share of Propack in a
deal that further cements the company's standing in the Chinese
market. The acquisition forms part of a major restructuring
exercise, in which the closure and...
Private equity firm, Direct Capital has acquired a shareholding of
51 per cent in New Zealand Pharmaceuticals (NZP). The investment by
Direct Capital aims to tap into the growing potential of
Merck has announced that its chairman of the executive board,
Bernhard Scheuble is to leave the company, by mutual agreement, in
a surprise departure considering the company's performance,
especially in its liquid crystals unit.